Guideline/Drug Updates and Errata
RxPrep content (e.g., NAPLEX Course Book, MPJE/CPJE Manuals and QBanks) is up-to-date at the time of publishing, but drug information and laws can change at any time. If information changes after a product is published, we will post exam-relevant updates in the Guideline/Drug Updates tables below. If we find anything that needs a correction or clarification it will be included in the Errata tables below.
Updates: 2023 RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2022-May 2023
Page | Update Type | Description |
---|---|---|
Chapters 15-17: Compounding I, II, and III | ||
p. 226-281 | Guideline Update | Revised United States Pharmacopeia (USP) chapters 795 (Nonsterile Preparations)
and 797 (Sterile Preparations) were published on November 1, 2022, and the changes will become official on
November 1, 2023. Since the changes will not be official until November 1, 2023, these updates are unlikely to
have an immediate impact on the compounding content tested on the NAPLEX. USP 795 USP 797 |
Chapter 31: Chronic Heart Failure and Chapter 44: Diabetes | ||
p. 466-469, 471 | Guideline Update | The American Heart Association (AHA) and American College of Cardiology (ACC)
released the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and aldosterone receptor antagonists are now considered initial medications for all patients with heart failure with reduced ejection fraction (HFrEF) without contraindications. 2022 AHA/ACC Heart Failure Guidelines |
Chapter 42: Chronic Obstructive Pulmonary Disease | ||
p. 590-591 | Guideline Update | The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released the
2023 guidelines for COPD diagnosis, management, and prevention. Key changes that could impact testing include:
|
Chapter 44: Diabetes | ||
p. 607-608 | Guideline Update | The 2023 American Diabetes Association (ADA) Standards of Care update was published. Key changes that could impact testing include: p. 607: Comprehensive Care, section on Cholesterol Control
p. 607: Comprehensive Care, section on Diabetic Kidney Disease
p. 607: Comprehensive Care, section on Blood Pressure Control
p. 608: Treatment for Type 2 Diabetes and Treatment Algorithm
|
Errata: 2023 RxPrep Course Book
Corrections or clarifications for the 2023 RxPrep Course Book
Page | Description | |
---|---|---|
Chapter 27: Dyslipidemia | ||
p. 426 | In the Statin Treatment Intensity Definitions and Selection Options table, pitavastain doses of 1-4 mg are considered moderate intensity. |
Guideline/Drug Updates: 2022 UWorld RxPrep Course Book
NAPLEX-relevant updates from June 2021-May 2022
Page | Update Type | Description |
---|---|---|
Chapter 18: Renal Disease and Chapter 44: Diabetes | ||
p. 292, 617 | Labeling Change | Dapagliflozin (Farxiga) has been FDA-approved for adults with chronic kidney disease to reduce the risk of eGFR decline, end-stage renal disease, cardiovascular death and hospitalization for heart failure. |
Chapter 20: Immunizations | ||
p. 324-331 | Guideline Update | The Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC) updated recommendations for several vaccines. Key changes that could impact testing include:
Pneumococcal vaccines
2022 CDC Adult Immunization Schedule ACIP/CDC Pneumococcal Vaccine Recommendations |
Chapter 23: Infectious Diseases II: Bacterial Infections | ||
p. 383 | Guideline Update | The Centers for Disease Control and Prevention (CDC) now recommend the following treatment options for latent tuberculosis (TB) in pregnant patients (without preference):
|
p. 393 | Guideline Update | The Infectious Diseases Society of America (IDSA) and the American College of Gastroenterologists (ACG) have both released updates for the treatment of Clostridioides difficile infection (CDI):
Infection in Adults ACG 2021 Clinical Guidelines for Clostridioides difficile Infections |
p. 394 | Guideline Update | The Sexually Transmitted Infections Treatment Guidelines, 2021 published by the Centers for Disease Control and Prevention contain an update for chlamydia treatment. The preferred regimens are:
|
Chapter 31: Chronic Heart Failure and Chapter 44: Diabetes | ||
p. 482, 617 | Labeling Change | Empagliflozin (Jardiance) has been FDA-approved to reduce the risk of cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction. |
Chapter 34: Anticoagulation | ||
p. 523 | Guideline Update | The American College of Chest Physicians (CHEST) released a second update to the Antithrombotic Therapy for the Treatment of Venous Thromboembolism (VTE) Disease guideline:
|
Chapter 44: Diabetes | ||
p. 614-616 | Guideline Update | The 2022 American Diabetes Association (ADA) Standards of Care update was published. Key changes that could impact testing include:
Screening
|
Chapter 44: Diabetes and Chapter 57: Weight Loss | ||
p. 618, 756 | Labeling Change | Semaglutide (Wegovy) injection has been FDA-approved for weight management in adults with obesity or who are overweight with at least one additional weight-related condition (e.g., hypertension, type 2 diabetes, dyslipidemia). |
Errata: 2022 UWorld RxPrep Course Book
Corrections or clarifications for the 2022 RxPrep Course Book
Page | Description | |
---|---|---|
Chapter 15: Compounding I | ||
p. 246 | On the clipboard describing USP 797 cleaning requirements, the minimum frequency of cleaning the carts should be monthly. | |
Chapter 18: Renal Disease | ||
p. 293 | In the section under Collecting Duct, the second to last sentence in the paragraph should say, “Potassium-sparing diuretics (including aldosterone antagonists) work in the distal convoluted tubule and collecting duct to decrease Na and water reabsorption and increase K reabsorption. |
Updates: 2023 RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2022-May 2023
Chapters 15-17: Compounding I, II, and III |
||
Page p. 226-281 |
Update type Guideline Update |
|
Revised United States Pharmacopeia (USP) chapters 795 (Nonsterile Preparations) and 797 (Sterile Preparations) were published on November 1, 2022, and the changes will become official on November 1, 2023. Since the changes will not be official until November 1, 2023, these updates are unlikely to have an immediate impact on the compounding content tested on the NAPLEX. USP 795 USP 797 |
||
Chapter 31: Chronic Heart Failure and Chapter 44: Diabetes |
||
Page p. 466-469, 471 |
Update type Guideline Update |
|
The American Heart Association (AHA) and American College of Cardiology (ACC) released the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and aldosterone receptor antagonists are now considered initial medications for all patients with heart failure with reduced ejection fraction (HFrEF) without contraindications. 2022 AHA/ACC Heart Failure Guidelines |
Errata: 2023 RxPrep Course Book
Corrections or clarifications for the 2023 RxPrep Course Book
Chapter 27: Dyslipidemia | ||
Page p. 426 |
||
In the Statin Treatment Intensity Definitions and Selection Options table, pitavastain doses of 1-4 mg are considered moderate intensity. |
Guideline/Drug Updates: 2022 UWorld RxPrep Course Book
NAPLEX-relevant updates from June 2021-May 2022
Chapter 18: Renal Disease and Chapter 44: Diabetes | ||
Page p. 292, 617 |
Update Type Labeling Change |
|
Dapagliflozin (Farxiga) has been FDA-approved for adults with chronic kidney disease to reduce the risk of eGFR decline, end-stage renal disease, cardiovascular death and hospitalization for heart failure. | ||
Chapter 20: Immunizations | ||
p. 324-331 | Update Type Guideline Update |
|
The Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC) updated recommendations for several vaccines. Key changes that could impact testing include:
Pneumococcal vaccines
2022 CDC Adult Immunization Schedule ACIP/CDC Pneumococcal Vaccine Recommendations |
||
Chapter 23: Infectious Diseases II: Bacterial Infections | ||
p. 383 | Update Type Guideline Update |
|
The Centers for Disease Control and Prevention (CDC) now recommend the following treatment options for latent tuberculosis (TB) in pregnant patients (without preference):
|
||
p. 393 | Update Type Guideline Update |
|
The Infectious Diseases Society of America (IDSA) and the American College of Gastroenterologists (ACG) have both released updates for the treatment of Clostridioides difficile infection (CDI):
Infection in Adults ACG 2021 Clinical Guidelines for Clostridioides difficile Infections |
||
p. 394 | Update Type Guideline Update |
|
The Sexually Transmitted Infections Treatment Guidelines, 2021 published by the Centers for Disease Control and Prevention contain an update for chlamydia treatment. The preferred regimens are:
|
||
Chapter 31: Chronic Heart Failure and Chapter 44: Diabetes | ||
Page p. 482, 617 |
Update Type Labeling Change |
|
Empagliflozin (Jardiance) has been FDA-approved to reduce the risk of cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction. | ||
Chapter 34: Anticoagulation | ||
Page p. 523 |
Update Type Guideline Update |
|
The American College of Chest Physicians (CHEST) released a second update to the Antithrombotic Therapy for the Treatment of Venous Thromboembolism (VTE) Disease guideline:
|
||
Chapter 44: Diabetes | ||
Page p. 614-616 |
Update Type Guideline Update |
|
The 2022 American Diabetes Association (ADA) Standards of Care update was published. Key changes that could impact testing include:
Screening
|
||
Chapter 44: Diabetes and Chapter 57: Weight Loss | ||
Page p. 618, 756 |
Update Type Labeling Change |
|
Semaglutide (Wegovy) injection has been FDA-approved for weight management in adults with obesity or who are overweight with at least one additional weight-related condition (e.g., hypertension, type 2 diabetes, dyslipidemia). |
Errata: 2022 UWorld RxPrep Course Book
Corrections or clarifications for the 2022 RxPrep Course Book
Chapter 15: Compounding I | ||
Page p. 246 |
||
On the clipboard describing USP 797 cleaning requirements, the minimum frequency of cleaning the carts should be monthly. | ||
Chapter 18: Renal Disease | ||
Page p. 293 |
||
In the section under Collecting Duct, the second to last sentence in the paragraph should say, “Potassium-sparing diuretics (including aldosterone antagonists) work in the distal convoluted tubule and collecting duct to decrease Na and water reabsorption and increase K reabsorption. |
MPJE Updates: 7th Edition Federal Law Summary for MPJE
MPJE-relevant updates from January 2021–Present
Page | Update Type | Description | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Chapter 1: Preparing for MPJE with RxPrep | ||||||||||||
p. 3-4 | Revised NABP MPJE Competency Statements
Effective March 2023 |
NABP has released revised MPJE Competency Statements (their blueprint of tested items). Impact for MPJE Candidates testing after March 1, 2023:
Comparison of previous and new MPJE Competency Areas:
Exam content will be distributed more evenly between the new Competency Areas. While the previous Area 3 of “General Regulatory Process” is not included in the new statements, the application of the material is likely still testable. For example:
Previous MPJE Competency statements (Prior to March 2023) New MPJE Competency Statements (Starting March 2023) |
||||||||||
Chapter 3: Pharmacy Operations | ||||||||||||
p. 44 | DEA Update
Effective October 2020 |
All controlled substances (schedule II – V) can be stored in a locked cabinet or
dispersed among other drugs. Prior to this change, schedule II drugs needed to be stored in a securely locked
cabinet or vault and could not be dispersed throughout the stock of non-controlled drugs.
2020 DEA Pharmacist’s Manual |
||||||||||
Chapter 4: Pharmacy Practice | ||||||||||||
p. 77 | Interchangeable Biosimilar Approval
Effective July 2021 |
The following update impacts the last sentence in the section under Biologics and Biosimilars.
The FDA approved two interchangeable biosimilar products in 2021. The following are interchangeable:
|
||||||||||
Chapter 8: Controlled Substance Part 3: Prescribing and Dispensing | ||||||||||||
p. 137, 154 -155 | Law Update
Effective June 2023 |
The following update impacts these sections:
On December 29, 2022, Congress eliminated the “DATA-Waiver Program” in order to increase access to buprenorphine and introduced new training requirements for all prescribers.
DEA Informational Document |
Chapter 3: Pharmacy Operations | ||
Page p. 44 |
Update type DEA Update Effective October 2020 |
|
All controlled substances (schedule II – V) can be stored in a locked cabinet or dispersed among other drugs. Prior to this change, schedule II drugs needed to be stored in a securely locked cabinet or vault and could not be dispersed throughout the stock of non-controlled drugs.
2020 DEA Pharmacist’s Manual |
||
Chapter 4: Pharmacy Practice | ||
Page p. 77 |
Update type Interchangeable Biosimilar Approval Effective July 2021 |
|
The following update impacts the last sentence in the section under Biologics and Biosimilars.
The FDA has now approved interchangeable biosimilar products. For example, the following are deemed interchangeable:
|
MPJE Errata: 7th Edition Federal Law Summary for MPJE
Corrections or clarifications for the 7th Edition Federal Law Summary for MPJE
Page | Description | |
---|---|---|
Chapter 4: Pharmacy Practice | ||
p. 65 | Regarding the prescription drugs that do not require child-resistant packaging, colesevelam powder should read ≤ 3.75 grams/package. | |
Chapter 8: Controlled Substances Part 3: Prescribing and Dispensing | ||
p. 154 | The 4th bullet in the Methadone Study Tip should read “(days 271 – 365).” |
Chapter 4: Pharmacy Practice | ||
Page p. 65 |
||
Regarding the prescription drugs that do not require child-resistant packaging, colesevelam powder should read ≤ 3.75 grams/package. | ||
Chapter 8: Controlled Substances Part 3: Prescribing and Dispensing | ||
Page p. 154 |
||
The 4th bullet in the Methadone Study Tip should read “(days 271 – 365).” |
CPJE Updates: 7th Edition California Law Summary for CPJE
CPJE-relevant updates from January 2021–Present
Page | Update Type | Description |
---|---|---|
Chapter 3: Pharmacy Practice Part I | ||
p. 52 | Interchangeable Biosimilar Approval Effective July 2021 |
The following update impacts the last sentence of the second paragraph under the Substituting Biologics section.
The FDA has now approved interchangeable biosimilar products. The approval allows for the substitution of approved biosimilars without the need for a separate prescription. For example, the following are deemed interchangeable:
|
Chapter 5: Controlled Substances Part 1: The Controlled Substances Act | ||
p. 96,98 | Law Update
Effective October 2021 |
California will now defer to the federal controlled substances scheduling rules and exemptions for barbituric acid (i.e., butalbital) and combinations with non-narcotics (e.g., acetaminophen). For example, Fioricet is no longer classified as schedule III in California.
The update above impacts the following:
|
Chapter 6: Controlled Substances Part 2: Ordering and Disposal | ||
p. 110 | Law Update
Effective April 2022 |
The following update impacts the Study Tip “Considerations to Determine if Loss or Theft is Significant.” The California Board of Pharmacy now defines the following as reportable significant loss of controlled substances:
|
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | ||
p. 120 & 121 | Revised California Security Forms
Effective January 1, 2021 |
The following updates were made to secure prescription form requirements:
Joint Statement Regarding Secure Prescription Forms 11/2020 |
p. 124 | Law Update
Effective January 2022 |
As of January 1, 2022, exceptions to the mandatory electronic prescribing (e-prescribing) law include:
|
p. 117, 131 – 132 | Law Update
Effective June 2023 |
The following update impacts these sections:
On December 29, 2022, Congress eliminated the “DATA-Waiver Program” in order to increase access to buprenorphine and introduced new training requirements for all prescribers.
|
Chapter 3: Pharmacy Practice Part I | ||
Page p. 52 |
Update Type Interchangeable Biosimilar Approval Effective July 2021 |
|
The following update impacts the last sentence of the second paragraph under the Substituting Biologics section.
The FDA has now approved interchangeable biosimilar products. The approval allows for the substitution of approved biosimilars without the need for a separate prescription. For example, the following are deemed interchangeable:
|
||
Chapter 5: Controlled Substances Part 1: The Controlled Substances Act | ||
Page p. 96,98 |
Update Type Law Update Effective October 2021 |
|
California will now defer to the federal controlled substances scheduling rules and exemptions for barbituric acid (i.e., butalbital) and combinations with non-narcotics (e.g., acetaminophen). For example, Fioricet is no longer classified as schedule III in California.
The update above impacts the following:
|
||
Chapter 6: Controlled Substances Part 2: Ordering and Disposal | ||
Page p. 110 |
Update Type Law Update Effective April 2022 |
|
The following update impacts the Study Tip “Considerations to Determine if Loss or Theft is Significant.” The California Board of Pharmacy now defines the following as reportable significant loss of controlled substances:
|
||
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | ||
Page p. 120 & 121 |
Update Type Revised California Security Forms Effective January 1, 2021 |
|
The following updates were made to secure prescription form requirements:
Joint Statement Regarding Secure Prescription Forms 11/2020 |
||
Page p. 124 |
Update Type Law Update Effective January 2022 |
|
As of January 1, 2022, exceptions to the mandatory electronic prescribing (e-prescribing) law include:
|
CPJE Errata: 7th Edition California Law Summary for CPJE
Corrections or clarifications for the 7th Edition California Law Summary for CPJE
Page | Description | |
---|---|---|
Chapter 2: Pharmacy Operations | ||
p. 24 | The last paragraph on the page should read: A pharmacy must contact the recipient (i.e., pharmacy, prescriber or patient) and board within 12 hours of the recall notice. An outsourcing facility must contact the recipient (i.e., pharmacy, prescriber or patient) and the board within 24 hours of the recall notice.
B&PC 4126.9, 4127.2, 4129.1 |
|
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | ||
p. 121 | Under the second bullet that states “Six quantity check-off boxes,” the second sub-bullet should read “May be checked by the prescriber to correspond to the written quantity of the drug.”
H&SC 11162.1 |
Chapter 2: Pharmacy Operations | ||
Page p. 24 |
||
The last paragraph on the page should read: A pharmacy must contact the recipient (i.e., pharmacy, prescriber or patient) and board within 12 hours of the recall notice. An outsourcing facility must contact the recipient (i.e., pharmacy, prescriber or patient) and the board within 24 hours of the recall notice.
B&PC 4126.9, 4127.2, 4129.1 |
||
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | ||
Page p. 121 |
||
Under the second bullet that states “Six quantity check-off boxes,” the second sub-bullet should read “May be checked by the prescriber to correspond to the written quantity of the drug.”
H&SC 11162.1 |